1. Sparsentan (Filspari) becomes the first approved treatment specifically for focal segmental glomerulosclerosis. 2. Clinical trial data show meaningful reductions ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. In this umbrella review, physical activity was effective in reducing the symptoms of depression and anxiety, not only in ...
1. Dapagliflozin reduced the risk of hospitalization in patients with chronic kidney disease (CKD) with and without type 2 diabetes ...
1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
1. In this secondary analysis of the DECLARE-TIMI 58 trial, among 17,160 patients, dapagliflozin consistently reduced the risk of cardiovascular ...
1. Lumasiran was shown to decrease urinary oxalate excretion in patients with Primary Hyperoxaluria Type 1. 2. Lumasiran was shown ...
Image: PD 1. Low birth weight is identified as a risk factor for later life hypertension and chronic kidney disease ...
Image: PD 1. Patients with heart failure, chronic kidney disease, and hypertension demonstrate increased chemosensitivity in the carotid body, contributing to increased ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
